241 related articles for article (PubMed ID: 17986282)
1. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.
Uemura M; Tamura K; Chung S; Honma S; Okuyama A; Nakamura Y; Nakagawa H
Cancer Sci; 2008 Jan; 99(1):81-6. PubMed ID: 17986282
[TBL] [Abstract][Full Text] [Related]
2. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
3. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
Negri-Cesi P; Colciago A; Poletti A; Motta M
Prostate; 1999 Dec; 41(4):224-32. PubMed ID: 10544295
[TBL] [Abstract][Full Text] [Related]
4. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.
Li J; Ding Z; Wang Z; Lu JF; Maity SN; Navone NM; Logothetis CJ; Mills GB; Kim J
PLoS One; 2011; 6(12):e28840. PubMed ID: 22194926
[TBL] [Abstract][Full Text] [Related]
5. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
6. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
[TBL] [Abstract][Full Text] [Related]
7. Hamster SRD5A3 lacks steroid 5α-reductase activity in vitro.
Chávez B; Ramos L; García-Becerra R; Vilchis F
Steroids; 2015 Feb; 94():41-50. PubMed ID: 25498908
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
Dadras SS; Cai X; Abasolo I; Wang Z
Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
11. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
12. Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.
Kaefer M; Audia JE; Bruchovsky N; Goode RL; Hsiao KC; Leibovitch IY; Krushinski JH; Lee C; Steidle CP; Sutkowski DM; Neubauer BL
J Steroid Biochem Mol Biol; 1996 May; 58(2):195-205. PubMed ID: 8809201
[TBL] [Abstract][Full Text] [Related]
13. Targeting 5α-reductase for prostate cancer prevention and treatment.
Nacusi LP; Tindall DJ
Nat Rev Urol; 2011 May; 8(7):378-84. PubMed ID: 21629218
[TBL] [Abstract][Full Text] [Related]
14. Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Klein H; Bressel M; Kastendieck H; Voigt KD
Am J Clin Oncol; 1988; 11 Suppl 2():S30-6. PubMed ID: 2853935
[TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
16. Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.
Dai C; Chung YM; Kovac E; Zhu Z; Li J; Magi-Galluzzi C; Stephenson AJ; Klein EA; Sharifi N
Clin Cancer Res; 2017 Oct; 23(20):6351-6362. PubMed ID: 28733443
[No Abstract] [Full Text] [Related]
17. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
18. The role of dihydrotestosterone in benign prostatic hyperplasia.
Carson C; Rittmaster R
Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
20. Androgen inactivation in human lung fibroblasts: variations in levels of 17 beta-hydroxysteroid dehydrogenase type 2 and 5 alpha-reductase activity compatible with androgen inactivation.
Provost PR; Blomquist CH; Drolet R; Flamand N; Tremblay Y
J Clin Endocrinol Metab; 2002 Aug; 87(8):3883-92. PubMed ID: 12161528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
